Posted inCardiagtech

MCTD Diagnosis: A Comprehensive Guide for Healthcare Professionals

No Comments

Introduction

Mixed Connective Tissue Disease (MCTD) is a complex and rare autoimmune disorder that presents a significant diagnostic challenge. Characterized by a unique antibody, anti-U1-ribonucleoprotein (RNP), alongside features overlapping with at least two other connective tissue diseases (CTDs) such as Systemic Lupus Erythematosus (SLE), Systemic Sclerosis (SSc), Inflammatory Myositis (IM), and Rheumatoid Arthritis (RA), MCTD’s variable presentation can delay accurate diagnosis. Patients often exhibit Raynaud phenomenon and a fluctuating constellation of symptoms, further complicating the diagnostic process. Effective management hinges on timely and precise Mctd Diagnosis, making it crucial for healthcare professionals to be well-versed in its diagnostic criteria, evaluation, and differential considerations. This article provides an in-depth guide to mctd diagnosis, drawing upon current clinical knowledge and established diagnostic approaches to aid in the accurate identification of this challenging condition.

Diagnostic Criteria for MCTD

Currently, there are no universally accepted international diagnostic criteria for MCTD. The diagnosis is often based on a combination of clinical features, serological findings, and expert clinical judgment. Several sets of criteria have been proposed over the years, reflecting the evolving understanding of this disease. Two commonly referenced sets of criteria are highlighted below, emphasizing the key elements necessary for mctd diagnosis.

Classic Diagnostic Criteria

The most widely used criteria for mctd diagnosis emphasize the presence of specific serological and clinical manifestations. These criteria generally require:

  • Serological Hallmark: The presence of a high titer of anti-U1-RNP antibodies. This is considered a mandatory criterion for mctd diagnosis.

  • Raynaud’s Phenomenon and Related Features: The presence of Raynaud phenomenon, along with either puffy digits or hand edema. These features are considered highly suggestive of MCTD and are crucial for initial clinical suspicion in mctd diagnosis.

And at least two of the following clinical features, indicative of overlapping connective tissue disease manifestations:

  • Synovitis: Inflammation of the synovial membrane, often presenting as joint pain, swelling, and stiffness.
  • Myositis: Muscle inflammation, characterized by muscle weakness and elevated muscle enzymes.
  • Leukopenia: A decreased white blood cell count.
  • Esophageal Dysmotility: Abnormal function of the esophagus, leading to swallowing difficulties.
  • Pleuritis: Inflammation of the lining of the lungs and chest cavity.
  • Pericarditis: Inflammation of the sac surrounding the heart.
  • Interstitial Lung Disease (ILD): A group of lung diseases characterized by scarring of the lung tissue.

Puffy fingers are a characteristic clinical feature often observed in patients undergoing mctd diagnosis, indicating soft tissue swelling.

Japanese Consensus Criteria (2019)

Recognizing the need for more refined diagnostic criteria, a consensus panel in Japan proposed a revised set in 2019. These criteria aim to improve the sensitivity and specificity of mctd diagnosis by categorizing disease features into organ involvement and overlapping manifestations. The Japanese criteria still require the presence of the anti-U1-RNP antibody and Raynaud phenomenon, but they offer a more structured approach to incorporating clinical features:

  • Mandatory Criteria:
    • High titer of positive anti-U1-RNP antibodies.
    • Raynaud phenomenon, puffy digits, or hand edema.

And either:

  • Organ Involvement (at least one):
    • Pulmonary arterial hypertension (PAH).
    • Aseptic meningitis.
    • Trigeminal neuropathy.

Or:

  • Overlapping Manifestations (at least two from different categories):
    • Systemic Lupus Erythematosus (SLE) Features: Polyarthritis, lymphadenopathy, malar rash, pericarditis or pleuritis, leukopenia or thrombocytopenia.
    • Systemic Sclerosis (SSc) Features: Sclerodactyly, interstitial lung disease, esophageal dysmotility or dilatation.
    • Inflammatory Myositis (IM) Features: Muscle weakness, elevated levels of myogenic enzymes, myogenic abnormalities on electromyogram (EMG).

Diagnosis according to the Japanese criteria is established by meeting at least one common manifestation (anti-U1-RNP antibody), immunological manifestation (Raynaud’s), and either one characteristic organ involvement or at least one feature in two or more overlapping manifestation categories. These criteria demonstrated high sensitivity (90.6%) and specificity (98.4%) in validation studies, offering a potentially more robust framework for mctd diagnosis, although they are not yet universally adopted.

Clinical Evaluation in MCTD Diagnosis

A thorough clinical evaluation is paramount in the process of mctd diagnosis. Given the varied and often nonspecific initial symptoms, a detailed patient history and physical examination are crucial.

History

The patient history should focus on:

  • Presenting Symptoms: Inquire about common initial symptoms such as arthralgia, myalgia, fatigue, and low-grade fever. Specifically, explore the presence, onset, frequency, and triggers of Raynaud phenomenon.
  • Systemic Review: Conduct a comprehensive review of systems to identify manifestations affecting various organs. This includes questions about skin changes (puffy fingers, scleroderma-like changes, rashes), musculoskeletal symptoms (joint pain, muscle weakness), cardiopulmonary symptoms (shortness of breath, chest pain, cough), gastrointestinal symptoms (dysphagia, reflux), and neurological symptoms (headaches, numbness, tingling).
  • Past Medical History: Investigate for any pre-existing autoimmune conditions or family history of autoimmune diseases, which may increase suspicion for MCTD.
  • Medication History: Review current and past medications, as some drugs can induce lupus-like syndromes or affect autoimmune responses.
  • Environmental Exposures: Explore potential environmental triggers such as exposure to silica, vinyl chloride, or certain infections, although a definitive environmental link for MCTD is not yet established.

Physical Examination

The physical examination should systematically assess for clinical signs suggestive of MCTD and its overlapping features:

  • Skin Examination: Assess for Raynaud phenomenon (triphasic color changes in fingers/toes upon cold exposure), puffy digits (diffuse swelling of fingers), sclerodactyly (thickening and tightening of skin on fingers), malar rash (butterfly-shaped rash across the cheeks and nose), discoid lesions, and nailfold capillary abnormalities (using nailfold capillaroscopy if available).
  • Musculoskeletal Examination: Evaluate for synovitis (joint swelling, tenderness, warmth, and limited range of motion), muscle weakness (particularly proximal muscle weakness), and muscle tenderness.
  • Cardiopulmonary Examination: Auscultate heart and lungs for abnormal sounds (murmurs, rubs, crackles), assess for signs of pulmonary hypertension (accentuated P2 heart sound, right ventricular heave), and evaluate for pleural effusion or pericardial effusion.
  • Gastrointestinal Examination: Assess for signs of esophageal dysmotility (observe for signs of aspiration, listen for bowel sounds), and evaluate for abdominal tenderness or organomegaly.
  • Neurological Examination: Assess cranial nerves, reflexes, sensation, and motor strength. Pay particular attention to signs of trigeminal neuropathy or peripheral neuropathy.

Raynaud’s phenomenon, a key indicator in mctd diagnosis, is visually assessed for characteristic color changes in the fingers and toes upon exposure to cold.

Laboratory Evaluation in MCTD Diagnosis

Laboratory testing plays a crucial role in confirming the clinical suspicion of MCTD and in excluding other conditions. The hallmark serological marker, the anti-U1-RNP antibody, is essential for mctd diagnosis.

Immunological Markers

  • Anti-U1-RNP Antibody: This antibody, detected by ELISA or other immunoassays, is the defining serological feature of MCTD. A high titer, typically considered significantly above the upper limit of normal, is required for mctd diagnosis. While highly sensitive (nearly 100%), it is not entirely specific to MCTD and can be found in other conditions, though usually at lower titers.
  • Antinuclear Antibody (ANA): ANA is typically positive in MCTD, often with a speckled pattern and high titer (>1:1280). While not specific, it supports the autoimmune nature of the disease.
  • Anti-SMN Complex Antibody: Emerging research suggests that anti-survival motor neuron (SMN) complex antibodies may be present in a subset of MCTD patients and could be associated with more severe disease, particularly pulmonary arterial hypertension and interstitial lung disease. While not yet part of standard diagnostic criteria, its presence may add to the diagnostic and prognostic evaluation.
  • Other Autoantibodies: Rheumatoid factor (RF) and anti-cyclic citrullinated peptide (anti-CCP) antibodies may be positive in some MCTD patients, reflecting the overlap with rheumatoid arthritis. However, antibodies more specific to other CTDs, such as anti-double-stranded DNA (dsDNA), anti-Smith (Sm), anti-Scl-70, and anti-centromere antibodies, are typically absent in classic MCTD and their presence may suggest disease evolution towards a more defined CTD.

General Laboratory Tests

  • Complete Blood Count (CBC): May reveal leukopenia (low white blood cell count), anemia, or thrombocytopenia (low platelet count).
  • Muscle Enzymes: Creatine kinase (CK) and aldolase levels may be elevated if myositis is present.
  • Erythrocyte Sedimentation Rate (ESR) and C-reactive protein (CRP): These inflammatory markers are often elevated in MCTD, reflecting systemic inflammation.
  • Urinalysis: May detect proteinuria or hematuria if renal involvement is present.
  • Complement Levels (C3, C4): May be reduced in some patients, particularly if there is overlap with SLE.
  • Hypergammaglobulinemia: Elevated levels of gamma globulins are frequently observed in MCTD.
  • False-positive VDRL: May occur due to the presence of antiphospholipid antibodies, although true antiphospholipid syndrome is less common in MCTD than in SLE.

Imaging and Diagnostic Studies in MCTD Diagnosis

Imaging and other diagnostic studies are not routinely used for mctd diagnosis itself but are essential for evaluating organ involvement and assessing disease severity once a diagnosis is suspected or confirmed.

Cardiopulmonary Investigations

  • Chest X-ray: Can screen for lung abnormalities such as interstitial infiltrates, pleural effusions, or cardiomegaly.
  • Echocardiogram: Evaluates for pulmonary hypertension, pericardial effusion, valvular abnormalities, and overall cardiac function.
  • Pulmonary Function Tests (PFTs): Assess lung volumes, diffusion capacity (DLCO), and airflow obstruction, helpful in detecting and monitoring interstitial lung disease. Reduced DLCO is a common finding in MCTD-related ILD.
  • Right Heart Catheterization: The gold standard for diagnosing pulmonary hypertension, measuring pulmonary artery pressures directly. Indicated if pulmonary hypertension is suspected based on clinical signs or echocardiogram findings.
  • High-Resolution Computed Tomography (HRCT) of the Chest: Provides detailed images of the lung parenchyma, crucial for characterizing interstitial lung disease patterns (e.g., nonspecific interstitial pneumonia – NSIP, the most common pattern in MCTD).

Musculoskeletal Investigations

  • Joint X-rays: May show erosions, joint space narrowing, or periarticular osteopenia in patients with inflammatory arthritis.
  • Musculoskeletal Ultrasound: Evaluates soft tissues, joints, and tendons for synovitis, tenosynovitis, and effusions.
  • Magnetic Resonance Imaging (MRI) of Muscles: Sensitive for detecting muscle inflammation (myositis) and can guide muscle biopsy if needed.

Other Diagnostic Studies

  • Esophagram and Upper Endoscopy: Evaluate esophageal dysmotility and rule out other causes of dysphagia.
  • Electromyography (EMG) and Nerve Conduction Studies: Assess for myopathic or neuropathic processes in patients with muscle weakness or neurological symptoms.
  • Renal Biopsy: May be indicated in cases of significant renal involvement (proteinuria, hematuria) to determine the specific type of nephropathy and guide treatment.

Differential Diagnosis in MCTD Diagnosis

Mctd diagnosis requires careful differentiation from other connective tissue diseases and related conditions, as overlapping features can make distinguishing them challenging. Key differential diagnoses include:

  • Systemic Lupus Erythematosus (SLE): While SLE shares many features with MCTD (arthritis, serositis, cytopenias), the presence of anti-dsDNA and anti-Smith antibodies, along with renal disease and specific mucocutaneous manifestations (e.g., discoid lupus), are more characteristic of SLE. The high titer anti-U1-RNP antibody is less specific for SLE and more indicative of MCTD in the context of overlapping features.
  • Systemic Sclerosis (SSc): Scleroderma-like skin changes, Raynaud phenomenon, and esophageal dysmotility are features shared by both MCTD and SSc. However, the presence of anti-centromere or anti-Scl-70 antibodies, as well as more pronounced skin fibrosis and specific organ involvement patterns (e.g., scleroderma renal crisis), are more typical of SSc.
  • Polymyositis/Dermatomyositis (PM/DM): Myositis is a feature of MCTD and PM/DM. However, PM/DM typically presents with more prominent proximal muscle weakness and may be associated with specific myositis-specific antibodies (MSAs) not typically found in MCTD. Dermatomyositis is further distinguished by characteristic skin rashes.
  • Rheumatoid Arthritis (RA): Synovitis is common to both MCTD and RA. RA is characterized by symmetric polyarthritis predominantly affecting small joints, and the presence of rheumatoid factor and anti-CCP antibodies. While these antibodies can be present in MCTD, they are not the primary diagnostic markers.
  • Undifferentiated Connective Tissue Disease (UCTD): UCTD refers to patients who have clinical features suggestive of a CTD but do not meet criteria for a specific defined CTD. Some patients initially diagnosed with UCTD may eventually evolve into MCTD or another defined CTD over time. In the early stages, distinguishing between UCTD and MCTD can be challenging, especially if the full spectrum of MCTD manifestations has not yet developed.

Conclusion

Accurate mctd diagnosis is crucial for effective management and improving patient outcomes. It requires a comprehensive approach integrating clinical evaluation, serological testing, and judicious use of imaging and diagnostic studies to assess organ involvement. While no single diagnostic criterion is universally accepted, utilizing established criteria sets, particularly those emphasizing the anti-U1-RNP antibody and overlapping CTD features, provides a robust framework for diagnosis. Differential diagnosis is essential to distinguish MCTD from other related conditions. Early recognition of MCTD and referral to a rheumatologist are critical steps in ensuring timely and appropriate care for patients with this complex autoimmune disease. An interprofessional healthcare team approach is vital for managing the diverse manifestations of MCTD and optimizing patient well-being.

References

  1. Sharp GC, Irvin WS, Tan EM, Gould RG, Holman HR. Mixed connective tissue disease–an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA). Am J Med. 1972 Feb;52(2):148-59.
  2. Bennett RM, O’Connell DJ. Mixed connective tisssue disease: a clinicopathologic study of 20 cases. Semin Arthritis Rheum. 1980 Aug;10(1):25-51.
  3. Gunnarsson R, Hetlevik SO, Lilleby V, Molberg Ø. Mixed connective tissue disease. Best Pract Res Clin Rheumatol. 2016 Feb;30(1):95-111.
  4. Alarcón-Segovia D, Cardiel MH. Comparison between 3 diagnostic criteria for mixed connective tissue disease. Study of 593 patients. J Rheumatol. 1989 Mar;16(3):328-34.
  5. Tanaka Y, Kuwana M, Fujii T, Kameda H, Muro Y, Fujio K, Itoh Y, Yasuoka H, Fukaya S, Ashihara K, Hirano D, Ohmura K, Tabuchi Y, Hasegawa H, Matsumiya R, Shirai Y, Ogura T, Tsuchida Y, Ogawa-Momohara M, Narazaki H, Inoue Y, Miyagawa I, Nakano K, Hirata S, Mori M. 2019 Diagnostic criteria for mixed connective tissue disease (MCTD): From the Japan research committee of the ministry of health, labor, and welfare for systemic autoimmune diseases. Mod Rheumatol. 2021 Jan;31(1):29-33.
  6. Kubo S, Tanaka Y. Evolution of diagnostic criteria and new insights into clinical testing in mixed connective tissue disease; anti-survival motor neuron complex antibody as a novel marker of severity of the disease. Immunol Med. 2024 Jun;47(2):52-57.
  7. Flåm ST, Gunnarsson R, Garen T, Norwegian MCTD Study Group. Lie BA, Molberg Ø. The HLA profiles of mixed connective tissue disease differ distinctly from the profiles of clinically related connective tissue diseases. Rheumatology (Oxford). 2015 Mar;54(3):528-35.
  8. Khanna A, Suri JC, Ray A, Sharma RK. Silica associated mixed connective tissue disorder in a stone crusher. Indian J Occup Environ Med. 2013 May;17(2):76-7.
  9. Prokop J, Jagodzinski PP. Identification of retroviral conserved pol sequences in serum of mixed connective tissue disease and systemic sclerosis patients. Biomed Pharmacother. 2004 Jan;58(1):61-4.
  10. Ranki A, Kurki P, Riepponen S, Stephansson E. Antibodies to retroviral proteins in autoimmune connective tissue disease. Relation to clinical manifestations and ribonucleoprotein autoantibodies. Arthritis Rheum. 1992 Dec;35(12):1483-91.
  11. Ungprasert P, Crowson CS, Chowdhary VR, Ernste FC, Moder KG, Matteson EL. Epidemiology of Mixed Connective Tissue Disease, 1985-2014: A Population-Based Study. Arthritis Care Res (Hoboken). 2016 Dec;68(12):1843-1848.
  12. Gunnarsson R, Molberg O, Gilboe IM, Gran JT., PAHNOR1 Study Group. The prevalence and incidence of mixed connective tissue disease: a national multicentre survey of Norwegian patients. Ann Rheum Dis. 2011 Jun;70(6):1047-51.
  13. Chevalier K, Thoreau B, Michel M, Godeau B, Agard C, Papo T, Sacre K, Seror R, Mariette X, Cacoub P, Benhamou Y, Levesque H, Goujard C, Lambotte O, Bonnotte B, Samson M, Ackermann F, Schmidt J, Duhaut P, Kahn JE, Hanslik T, Costedoat-Chalumeau N, Terrier B, Regent A, Dunogue B, Cohen P, Guern VL, Hachulla E, Chaigne B, Mouthon L. Clinical presentation, course, and prognosis of patients with mixed connective tissue disease: A multicenter retrospective cohort. J Intern Med. 2024 Apr;295(4):532-543.
  14. Greidinger EL, Zang YJ, Jaimes K, Martinez L, Nassiri M, Hoffman RW. CD4+ T cells target epitopes residing within the RNA-binding domain of the U1-70-kDa small nuclear ribonucleoprotein autoantigen and have restricted TCR diversity in an HLA-DR4-transgenic murine model of mixed connective tissue disease. J Immunol. 2008 Jun 15;180(12):8444-54.
  15. S L, Tony K, Raghupathy, V S, Malepati B. A Rare Case of Mixed Connective Tissue Disease (MCTD) with Intricate Features of Lupus, Polymyositis and Rheumatoid Arthritis Presenting with Severe Myositis. J Clin Diagn Res. 2015 Mar;9(3):OD05-7.
  16. Venables PJ. Mixed connective tissue disease. Lupus. 2006;15(3):132-7.
  17. Zdrojewicz Z, Budzyń-Kozioł E, Puławska J. [Mixed connective tissue disease–etiology, pathogenesis, clinical significance, treatment]. Postepy Hig Med Dosw. 1999;53(5):751-66.
  18. Okawa-Takatsuji M, Aotsuka S, Uwatoko S, Takaono M, Iwasaki K, Kinoshita M, Sumiya M. Endothelial cell-binding activity of anti-U1-ribonucleoprotein antibodies in patients with connective tissue diseases. Clin Exp Immunol. 2001 Nov;126(2):345-54.
  19. Biggiogera M, Bottone MG, Martin TE, Uchiumi T, Pellicciari Still immunodetectable nuclear RNPs are extruded from the cytoplasm of spontaneously apoptotic thymocytes. Exp Cell Res. 1997 Aug 01;234(2):512-20.
  20. Alves MR, Isenberg DA. “Mixed connective tissue disease”: a condition in search of an identity. Clin Exp Med. 2020 May;20(2):159-166.
  21. Ornowska S, Wudarski M, Dziewięcka E, Olesińska M. Naifold capillaroscopy in mixed connective tissue disease patients. Clin Rheumatol. 2024 May;43(5):1703-1709.
  22. Varma R, Szilagyi S, Harshan M. Breast involvement in mixed connective tissue disease. Radiol Case Rep. 2019 Apr;14(4):430-435.
  23. Nakashima M, Suzuki K, Okada M, Kataharada K, Takada K, Nakanishi T, Kobayashi M, Ohsuzu F. Panniculitis in a patient with mixed connective tissue disease. Mod Rheumatol. 2004;14(3):250-3.
  24. Sullivan WD, Hurst DJ, Harmon CE, Esther JH, Agia GA, Maltby JD, Lillard SB, Held CN, Wolfe JF, Sunderrajan EV. A prospective evaluation emphasizing pulmonary involvement in patients with mixed connective tissue disease. Medicine (Baltimore). 1984 Mar;63(2):92-107.
  25. Prakash UB. Lungs in mixed connective tissue disease. J Thorac Imaging. 1992 Mar;7(2):55-61.
  26. Ungprasert P, Wannarong T, Panichsillapakit T, Cheungpasitporn W, Thongprayoon C, Ahmed S, Raddatz DA. Cardiac involvement in mixed connective tissue disease: a systematic review. Int J Cardiol. 2014 Feb 15;171(3):326-30.
  27. Furuya T, Suzuki T, Onoda N, Tamura K, Sato K, Demura H, Kashiwazaki S. Mixed connective tissue disease associated with protein losing enteropathy: successful treatment with intravenous cyclophosphamide therapy. Intern Med. 1992 Dec;31(12):1359-62.
  28. Murakami T, Endo S, Moriki T, Doi T, Matsumoto Y. Mixed connective tissue disease developing into MPO-ANCA-positive polyangiitis. Intern Med. 2011;50(6):591-5.
  29. Kitridou RC, Akmal M, Turkel SB, Ehresmann GR, Quismorio FP, Massry SG. Renal involvement in mixed connective tissue disease: a longitudinal clinicopathologic study. Semin Arthritis Rheum. 1986 Nov;16(2):135-45.
  30. Bennett RM, Bong DM, Spargo BH. Neuropsychiatric problems in mixed connective tissue disease. Am J Med. 1978 Dec;65(6):955-62.
  31. Agrawal A, Kohat AK, Sahu C, Kansal C, Fatima A. Headache and cerebral venous sinus thrombosis as a first presentation of mixed connective tissue disease: a rare case and literature review. Acta Neurol Belg. 2024 Oct;124(5):1741-1743.
  32. Todoroki Y, Satoh M, Kubo S, Kosaka S, Fukuyo S, Nakatsuka K, Saito K, Tanaka S, Nakayamada S, Tanaka Y. Anti-survival motor neuron complex antibodies as a novel biomarker for pulmonary arterial hypertension and interstitial lung disease in mixed connective tissue disease. Rheumatology (Oxford). 2024 Apr 02;63(4):1068-1075.
  33. García-de la Torre I, Salazar-Páramo M, Salmón-de la Torre G. Mixed connective tissue disease. A clinico-serological study of 17 cases. Mol Biol Rep. 1996;23(3-4):153-7.
  34. Takasaki Y, Yamanaka K, Takasaki C, Matsushita M, Yamada H, Nawata M, Matsudaira R, Ikeda K, Kaneda K, Hashimoto H. Anticyclic citrullinated peptide antibodies in patients with mixed connective tissue disease. Mod Rheumatol. 2004;14(5):367-75.
  35. Kozuka T, Johkoh T, Honda O, Mihara N, Koyama M, Tomiyama N, Hamada S, Nakamura H, Ichikado K. Pulmonary involvement in mixed connective tissue disease: high-resolution CT findings in 41 patients. J Thorac Imaging. 2001 Apr;16(2):94-8.
  36. Tashkin DP, Roth MD, Clements PJ, Furst DE, Khanna D, Kleerup EC, Goldin J, Arriola E, Volkmann ER, Kafaja S, Silver R, Steen V, Strange C, Wise R, Wigley F, Mayes M, Riley DJ, Hussain S, Assassi S, Hsu VM, Patel B, Phillips K, Martinez F, Golden J, Connolly MK, Varga J, Dematte J, Hinchcliff ME, Fischer A, Swigris J, Meehan R, Theodore A, Simms R, Volkov S, Schraufnagel DE, Scholand MB, Frech T, Molitor JA, Highland K, Read CA, Fritzler MJ, Kim GHJ, Tseng CH, Elashoff RM., Sclerodema Lung Study II Investigators. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med. 2016 Sep;4(9):708-719.
  37. Maher TM, Tudor VA, Saunders P, Zanghelini F, Grossi Sampedro C, Xydopoulos G, Gibbons M, Fletcher SV, Denton CP, Kokosi M, Hoyles RK, Parfrey H, Renzoni EA, Wells AU, Ashby D, Fordham RJ, Szigeti M, Molyneaux PL. Rituximab compared to intravenous cyclophosphamide in adults with connective tissue disease-associated interstitial lung disease: the RECITAL RCT. National Institute for Health and Care Research; Southampton (UK): Feb, 2024.
  38. Hajas A, Szodoray P, Nakken B, Gaal J, Zöld E, Laczik R, Demeter N, Nagy G, Szekanecz Z, Zeher M, Szegedi G, Bodolay E. Clinical course, prognosis, and causes of death in mixed connective tissue disease. J Rheumatol. 2013 Jul;40(7):1134-42.
  39. Gunnarsson R, El-Hage F, Aaløkken TM, Reiseter S, Lund MB, Garen T, Norwegian MCTD study group. Molberg Ø. Associations between anti-Ro52 antibodies and lung fibrosis in mixed connective tissue disease. Rheumatology (Oxford). 2016 Jan;55(1):103-8.
  40. Escolà-Vergé L, Pinal-Fernandez I, Fernandez-Codina A, Callejas-Moraga EL, Espinosa J, Marin A, Labrador-Horrillo M, Selva-O’Callaghan A. Mixed Connective Tissue Disease and Epitope Spreading: An Historical Cohort Study. J Clin Rheumatol. 2017 Apr;23(3):155-159.
  41. Chaigne B, Scirè CA, Talarico R, Alexander T, Amoura Z, Avcin T, Beretta L, Doria A, Guffroy A, Guimarães V, Hachulla É, Krieg T, Launay D, Lepri G, Moinzadeh P, Müller-Ladner U, Rednic S, Rodrigues A, Tas SW, van Vollenhoven RF, Vieira A, Bombardieri S, Fonseca JE, Galetti I, Schneider M, Smith V, Cutolo M, Mosca M, Fischer-Betz R. Mixed connective tissue disease: state of the art on clinical practice guidelines. RMD Open. 2018;4(Suppl 1):e000783.

Comments

No comments yet. Why don’t you start the discussion?

Leave a Reply

Your email address will not be published. Required fields are marked *